334 results about "Anaphylactic reactions" patented technology

Methods and devices for treating bronchial constriction related to asthma and anaphylaxis wherein the treatment includes providing an electrical impulse to a selected region of the vagus nerve and / or the lungs of a patient suffering from bronchial constriction.

The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

The present invention relates to methods of administering a series of epinephrine doses for the treatment of allergic emergencies, including anaphylaxis, comprising buccal, lingual or sublingual epinephrine dosage forms and injectable epinephrine dosage forms. Also provided herein are kits and packaging systems useful in these methods.

The invention relates to a mixed gel consisting of polymethyl methacrylate and cross bonding hyaluronic acid, which is applied to injection, and a preparation method thereof; the mixed gel of the invention is characterized in that polymethyl methacrylate microballoon, cross bonding hyaluronic acid gel particles and hyaluronic acid or salting liquid thereof form the mixed gel, wherein, the polymethyl methacrylate microballoon accounts for 0.5-30% in terms of volume, volume ratio of the cross bonding hyaluronic acid gel particles and hyaluronic acid or salting liquid thereof ranges from 1:19 to19:1. The method for preparing the mixed gel comprises respectively preparing the polymethyl methacrylate microballoon and cross bonding hyaluronic acid gel particles, then evenly mixing the microballoon and the gel particles with hyaluronic acid or salt thereof dissolved in isosmotic solution, the sterilizing and packaging the mixture to obtain the finished product. The mixed gel of the invention can be used to prepare injection applied to beauty care and medical treatment and is a highly effective and lasting moulding material, which has the advantages of less side-effect and low incidence rate of anaphylactic reaction.

The present invention relates to methods of administering dosage forms which comprise epinephrine, including buccal, lingual, sublingual or transmucosal dosage forms comprising epinephrine for treatment of allergic emergencies, including anaphylaxis. Also provided herein are kits and packaging systems useful in these methods.

The invention provides a composition including epinephrine nanoparticles and methods for therapeutic use of the composition in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.

Submandibular peptides have been isolated and characterised and provide pharmaceutical compositions for the treatment or prevention of anaphylactic reactions, endotoxic reactions and SIRS-induced shock.

A driving-bird composite contains the following materials by different weight percentage: the driving-bird spice is selected from: 1 to 50 percent of methyl ortho-aminobenzoate, one or two of the 0.1-5 percent of heartleaf houttuynia herb essential oil or 10-21 percent of muskiness T; an antioxidant is selected from one or two of the 0.02-0.5 percent of 2, 6-BHT and sodium ascorbate, and the rest is control-released carriers. The driving-bird colloid mixture is made of the driving-bird composite, and the control-released carrier contains organic base or inorganic base, unsaturated fatty acid, antiseptic, emulsification, stabilizing agent, anti-freeze agent and the like. The driving-bird SC is made of the driving-bird composite, and the control-released carrier contains michael essien alkenyl succinic acid ester of starch sodium or Beta-cyclodextrin, antiseptic, emulsification, stabilizing agent, anti-freeze agent and the like. The invention utilizes the odor of the driving-bird spice for leading the bird-trigeminal to generate anaphylactic reaction and the bird-physiology to generate anorexia after pecking by means of diluting the sprayer, the driving-bird composite has the advantages of convenient usage and good effect of driving, and is harmless to the birds and the plant, thus belonging to the environment friendly biological agent products.

The invention is a functional skin care product containing purslane extractive. Raw materials of the functional skin care product include, by weight, 10 parts of purslane extractive, 1-2 parts of Prinsepia utilis rogle oil, 2-5 parts of glycerol, 0.3-0.5 parts of crylic acid (ester) / C10-30 alkanol acrylate cross-linked polymer, 2-3 parts of 1,2-pentanediol, 1-5 parts of synthesized squalane, 1-2 parts of tocopheryl acetate, 2-3 parts of cetostearyl alcohol, 0.1-0.2 part of allantoin, 0.3-0.8 part of sodium hyaluronate, 3-5 parts of Butyrospermum parkii butter, and 100 parts of deionized water. Or the Prinsepia utilis rogle oil and the Butyrospermum parkii butter are not added. By the aid of animal experiments, namely, mouse auricle swelling models due to dimethlbenzene, the functional skin care product containing purslane extractive is fine in anti-inflammation and anti-allergy effects, mild in nature and fine in safety, and is free of toxic reaction and anaphylaxis. The functional skin care product has an adjuvant therapy function to skin barrier recovery of common discosmetic dermatosis such as hormone dependent dermatitis and acne, and is fine in curative effect and safety.

The present invention provides methods of treating IgE-associated disorders and compositions for use therein. The methods are particularly useful in treatment of allergies and allergy-related disorders. The methods generally comprise administering an IgE inhibitor (such as anti-IgE antibody) and an antigen and / or immunostimulatory polynucleotide sequence (ISS). These combination methods offer significant advantages, such as allowing more aggressive therapy while reducing unwanted side effects, such as anaphylaxis.

The present invention relates to novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof. The present invention more particularly provides novel hetereocycles of the general formula (I). Also included is a method of treatment of immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection in a mammal comprising administering an effective amount of a compound of formula (I) as described above.

The present invention relates to compounds having the general structure: and pharmaceutically acceptable salts and hydrates thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

The present invention relates to methods of prophylactically treating, reducing, delaying or controlling severe allergic reaction, e.g., to food and / or hymenoptera allergen, e.g. peanut allergen or bee venom allergen, in patients at risk of systemic anaphylaxis, e.g., patients receiving allergen desensitization therapy, through the use of a mast cell stabilizer, e.g., ketotifen and / or its metabolites or derivatives in free or pharmaceutically acceptable acid addition salts thereof. The invention further provides methods to desensitize a patient to one or more allergens comprising administering (i) one or more allergen to induce tolerance and (ii) one or more mast cell stabilizers in free or pharmaceutically acceptable salt thereof.

The invention discloses a peony moisturizing lotion. The peony moisturizing lotion is prepared from, by mass, 5-30% of a rose extracting solution, 5-50% of a peony flower extracting solution, 8-10% of a peony bark extracting solution, 2-5% of a licorice root extracting solution, 0.5-2% of sodium hyaluronate with the average molecular weight smaller than 10<4>Da, 0.5-2% of sodium hyaluronate with the average molecular weight being 10<6>Da, 0.1-0.5% of polyglutamic acid, 2-5% of glycerol, 0.5-2% of peony seed oil and the balance deionized water. The invention further discloses a preparation method of the peony moisturizing lotion. The peony moisturizing lotion has the long-acting moisturizing, whitening and wrinkle removing and antisepsis and anti-inflammation effects, is safe, stable and not greasy, can fast improve the moisture holding capacity of skin and motivate the vitality of cells, has the functions of keeping the kin moist and preventing the skin from being dry and becoming dark, and is high in safety, suitable for skin in various types and free of anaphylactic reaction.

The invention relates to the field of natural dyes and application thereof and aims to provide a method for preparing a photinia fruit natural dye and application of the photinia fruit natural dye. The preparation method comprises the following steps of: (1) washing and airing fresh photinia fruits and dried photinia fruits, and mechanically crushing the fruits; and (2) adding the crushed photinia fruits into aqueous solution of ethanol for reflux extraction, raising the temperature of the extract to between 70 and 90 DEG C, keeping the temperature, filtering and distilling under reduced pressure to make the volume of concentrated solution 1 / 6 to 1 / 2 of the original volume of the extract so as to obtain the concentrated photinia fruit natural dye. The method for preparing the photinia fruit natural dye has the advantages of simple extraction technology, extraction efficiency obviously higher than that of ethanol reflux and other methods, and no environmental pollution in the extraction process; and the extract has the advantages of good color fastness to protein fibers, capacity of increasing color spectrum after dyeing by using environment-friendly dye mordant treatment, gentle color and safe wear of the dyed fabrics without carcinogenic, teratogenetic actions or anaphylactic reaction, high ecological environment compatibility, biodegradation, low price, full utilization of natural resources and wide market prospect.

The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including asthma, food allergies, hypersensitivity and anaphylactic reactions.

The invention provides a compound disinfectant and a preparation method, the compound disinfectant comprises the following components: 0.5-10.0g / L of iodine, 0.5-2.0g / L of quaternary ammonium salt, 0.2-3.0g / L of potassium iodide, 10g / L-30g / L of polyethylene glycol, 2.5-25.0g / L of nonionic surfactant and the balance of deionized water. The quaternary ammonium salt preferably selects a mixture of single chain quaternary ammonium salt and double-chain quaternary ammonium salt. The invention also provides an application of the compound disinfectant for killing virus and bacteria on skin, mucous membrane, wound, hand and object surface. While in use, the compound skin mucous membrane disinfectant has no irritation on skin mucous membrane, no toxic and side effect, no anaphylactic reaction, convenient usage, wide application scope and rapid effect, and has microbe killing effect. The compound skin mucous membrane disinfectant has reliable effect for various pathogenic microorganism, can kill envelope-free virus in 3 minutes, and is an important means for preventing and controlling various infectious diseases.

The present disclosure relates to integrated systems, methods and apparatuses for assisting individuals in managing acute life-threatening conditions. A system in accordance with the current disclosure may comprise an electronic circuit configured to be attached to a container of a medication and one or more devices in communication with the electronic circuit in a private network. In an aspect, the one or more devices may work in concert to determine the safety level of an individual based on predetermined usage settings. In some aspects, the system may be configured to determine whether a medication would expire before its manufactured expiry date. In another aspect, the system may assist an individual in locating a medication. In a further aspect, the system may determine whether an individual is having an anaphylactic reaction. In some aspects, the system may detect a known allergen and alert the individual.

The invention relates to penicillium protein elicitor EPTP and application thereof in improving plant disease resistance. The protein sequence of the EPTP protein elicitor is shown as SEQ ID NO.2, and the molecular weight is 19247 Da. EPTP induces significant increase of activity of phenylalanine ammonialyase, peroxidase and polyphenol oxidase, and when the elicitor induces tobacco anaphylactic reaction, an anaphylactic reaction marker gene hin1 is induced to express; it is indicated through semiquantitative RT-PCR results that EPTP can induce tobacco to obtain systemic acquired resistance, cause up-regulation of the tobacco blade resistance gene transcription level, and induce expression of resistance gene related to the salicylic acid path and the jasmonic acid path. After being applied, EPTP can improve resistance to viruses and pathogenic bacteria by plants, takes effects efficiently, does not pollute environment, reduces dosage of chemical pesticide and has wide application prospects as a plant immunity activator.

The invention discloses a preparation method of a taxol / DNA tetrahedral drug loading system and belongs to the field of biological drugs. The preparation method includes: mixing a taxol solution with a DNA tetrahedral solution, hatching, then centrifuging, and removing supernate to obtain the taxol / DNA tetrahedral drug loading system. The preparation method has the advantages that the water solubility of PTX is increased, the anaphylactic reaction of an existing PTX solvent which is the mixture of polyoxyethylated castor oil and anhydrous ethanol, lethal dose of 50% is lowered, the resource limitation problem is relieved effectively, the drug tolerance of the PTX can be reversed, and lethality to drug-tolerant tumors is increased.

Cefquinome liposome, which belongs to the field of pharmaceutics, has a particle size of less than 1000 nm, and is mainly prepared from the following raw materials by weight: 1 part of cefquinome, 1-40 parts of phospholipid, 0-15 parts of sterol or soy isoflavone glucoside or soyasapogenol, and 0-15 parts of additives. The cefquinome liposome can be prepared into a liquid preparation, and can also be prepared into a solid preparation by adding a proper amount of a support agent. The cefquinome liposome or cefquinome long circulating liposome prepared in the invention contains no irritant substances, and can relieve anaphylactic reaction; the obtained preparation has good stability, has an average liposome particle size of less than 1000 nm, and has encapsulation efficiency of more than 80%. The preparation method is mature in process, simple, practical, and suitable for industrial production.

The invention relates to the technical field of amorphous alloy application, particularly to an amorphous alloy spectacle frame and glass and a production method thereof. The amorphous alloy spectacle frame is made of Zr-based amorphous alloy, has a strength of 1400-2300 MPa, an elastic limit of 2-2.5%, a Vickers hardness of 530-600 and a nickel release quantity of 0.005-0.015 mg / cm2 / week, and is smooth in surface without corrosion after bearing a salt spray test for 336-480 hours. Due the fact that the amorphous alloy spectacle frame and glass is low in nickel release quantity during usage, a wearer can avoid any anaphylactic reactions during long-term wearing. Besides, the production method of the Zr-based amorphous alloy spectacle frame has the advantages of being simple in production process, high in production efficiency and low in production cost; the produced amorphous alloy spectacle frame has the advantages of being long in service life.

The invention discloses a preparation method of a rubber and plastic synthetic ultrathin condom. The preparation method comprises the following steps: by taking synthesized polyisoprene as a matrix, adding the synthesized polyisoprene, water-based polyurethane, natural rubber latex, KOH, ammonia water and an initiator under a certain condition, thereby synthesizing the condom prepared from a composite high polymer material. According to the preparation method of the rubber and plastic synthetic ultrathin condom disclosed by the invention, the preparation method adopting the synthesized polyisoprene, a little natural rubber latex and water-based polyurethane is used to substitute the original natural rubber latex process to prepare a condom product. The condom is not added with vulcanizing agents sulfur, zinc oxide, an accelerator, and the like, is slightly influenced by environment, and is increased in product qualified rate; the raw materials are good in performance and can be used for preparing the ultrathin condom which has the advantages of good skin affinity, no water-soluble proteins, no anaphylactic reaction on the human body, and the like.

The present invention relates to methods of administering dosage forms which comprise epinephrine, including buccal, lingual, sublingual or transmucosal dosage forms comprising epinephrine for treatment of allergic emergencies, including anaphylaxis. Also provided herein are kits and packaging systems useful in these methods.

The invention discloses a titanium alloy spectacle frame and a preparation method thereof. The titanium alloy spectacle frame is characterized in that titanium alloy comprises the components of metalA, metal B, the balance titanium and inevitable impurities; the metal A is metal with the melting point higher than the melting point of Ti by a range within 600 DEG C, and the metal B is metal with amelting point lower than the melting point of Ti by a range within 200 DEG C; and the metal A comprises one kind or several kinds of platinum, zirconium and hafnium, and the metal B comprises one kind or several kinds of lutetium, palladium, erbium, thulium, scandium, yttrium, iron and cobalt. The preparation method is characterized in that the titanium alloy spectacle frame is obtained through the steps of preparing intermediate alloy, preparing the titanium alloy and producing the titanium alloy spectacle frame. The titanium alloy spectacle frame produced by the method is light in weight, is firm, is good in biocompatibility with a human body, does not contain elements such as nickel which easily causes anaphylactic reaction, is good in glossiness, conforms to the public aesthetic judgment and is good in elasticity, the comfort experience is brought to a wearer, and the problem of falling off caused by large deformation can not be caused.

The invention discloses a fully degradable polylactic acid fiber spunlace fabric and a preparation method thereof. The spunlace fabric with the thickness of 0.2-1.2mm is prepared by adopting polylactic acid fiber with the fineness of 0.6-1.2dtex and the length of 25-72mm to perform crossing and netting, spunlacing and tangling and drying. The polylactic acid fiber spunlace fabric of the inventionhas high absorptivity, good air permeability and other good performances, and is fully natural without skin irritation and allergic reaction, thus being applicable to the production of the surface material of baby care products and female care products. The preparation method of the invention has simple and practical process, thus being applicable to industrialized production.

The invention discloses an amoxicillin particle and a preparation process thereof. In the preparation process of the amoxicillin particle, a low-moisture volatile adhesive solution and a cold drying technology are adopted. The invention has the advantages that the stability of the amoxicillin particle is enhanced; and within the 36-month valid period of the amoxicillin particle, the safety and validness of the amoxicillin particle in clinical use are ensured, and no penicillin anaphylaxis is generated.

The invention is concerned with a kind of dispensation of invigorating the spleen and tonifying the kidney preparation and its preparation method. It relates to raw milkvetch root, raw red sage root, Rhizoma Dioscoreae, raw bighead atractylodes rhizome, broomrape, roud cardamon seed, raw rhubarb, raw liquorice, and so on. Dry, grind, soak, boil out, boil out again, mix about materials to get the said preparation. It bases on traditional Chinese medicine theory and the correlation theory of five parenchymatous viscera. This dispensation is fit for chronic kidney disease without anaphylactic response and side effect. It can release many clinical symptoms, such as spontaneous perspiratio and fatigue, short of breath and want of speech, yellowish complexion and emaciation, inappetence and abdominal distension, improve the kidney function and nutriture to prolong survival time of sufferers. It has low cost and easy preparation technology.

The invention discloses a Japanese saussurea herb extracting solution as well as a preparation method and application thereof. The Japanese saussurea herb extracting solution prepared in a water extract manner is obtained by a lot of experiments and researches of the inventor. The Japanese saussurea herb extracting solution has the characteristic that skin contact anaphylaxis is significantly removed, so that cosmetics containing the Japanese saussurea herb extracting solution have good action on people with sensitive skin, and the using effects of the cosmetics on people with sensitive skin are improved.

The invention provides methods and reagents useful for detecting anti-drug antibodies of IgE isotype to therapeutic anti-IgE antibodies, and methods for assessing risk of anaphylaxis to administration of a therapeutic anti-IgE antibody.